The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.
Diagnosis as acute ischemic stroke according to the Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018;
First clinical onset or previous presence of cerebral infarction without severe sequelae（Premorbid mRS ≤2）
Age≥18 years, male or female;
3≤Baseline NIHSS≤25;
Cerebral hemorrhage and the acute phase of other hemorrhagic diseases；
Previously allergic or intolerant to injectable HUK；
Used ACEI drugs prior to medication and less than 5 half-lives of the drug (according to the specific drug instructions) or received ACEI drugs during the study period;
Stent surgery after the AIS onset or planned interventional therapy;